S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
S&P 500   3,970.79 (+0.56%)
DOW   32,244.04 (+0.43%)
QQQ   309.82 (+0.02%)
AAPL   159.53 (+0.38%)
MSFT   279.16 (+0.54%)
META   205.54 (+0.62%)
GOOGL   104.99 (-0.58%)
AMZN   97.85 (-0.87%)
TSLA   190.23 (-1.04%)
NVDA   266.34 (-2.05%)
NIO   9.06 (-2.27%)
BABA   86.72 (+0.23%)
AMD   97.79 (-2.48%)
T   18.61 (+0.81%)
F   11.45 (+0.26%)
MU   60.73 (-0.99%)
CGC   1.92 (+0.26%)
GE   90.91 (-0.74%)
DIS   93.90 (-2.01%)
AMC   4.47 (+0.00%)
PFE   40.30 (+0.30%)
PYPL   73.42 (+1.19%)
NFLX   328.44 (+2.52%)
LON:SLN

Silence Therapeutics - SLN Share Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
535
▼
535
52-Week Range
N/A
Volume
913,528 shs
Average Volume
80,100 shs
Market Capitalization
£480.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SLN stock logo

About Silence Therapeutics (LON:SLN) Stock

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Stock News Headlines

March 19, 2023 | americanbankingnews.com
Silence Therapeutics (LON:SLN) Shares Pass Below Two Hundred Day Moving Average of $535.00
February 8, 2023 | finance.yahoo.com
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 6, 2023 | wsj.com
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
January 12, 2023 | finance.yahoo.com
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
November 10, 2022 | finanznachrichten.de
Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2022 Results
September 29, 2022 | finance.yahoo.com
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
September 27, 2022 | finance.yahoo.com
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
August 13, 2022 | finanznachrichten.de
Silence Therapeutics plc: Silence Therapeutics Announces Pricing of Underwritten Offering
July 15, 2022 | wsj.com
Silence Therapeutics PLC ADR
June 17, 2022 | benzinga.com
Silence Therapeutics (NASDAQ:SLN), Short Interest Report
May 18, 2022 | finance.yahoo.com
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
March 23, 2022 | seekingalpha.com
Silence Therapeutics to get $3M from Mallinckrodt as trial application for SLN501 filed
March 23, 2022 | finance.yahoo.com
Silence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501
March 17, 2022 | finanznachrichten.de
Silence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
March 17, 2022 | benzinga.com
Silence Therapeutics Reports FY21 Sales £12.4M Up From £5.5M YoY
March 17, 2022 | finance.yahoo.com
Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
February 26, 2022 | seekingalpha.com
Silence Therapeutics granted Orphan Drug status for rare blood disorder candidate
February 9, 2022 | finance.yahoo.com
Silence Therapeutics Posts First Human Data For Cardiovascular Candidate
January 18, 2022 | finance.yahoo.com
Silence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of Directors
January 5, 2022 | finance.yahoo.com
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference
December 16, 2021 | finanznachrichten.de
Silence Therapeutics plc: Silence Therapeutics Begins Exclusive Nasdaq Trading
November 30, 2021 | finance.yahoo.com
Silence Therapeutics Begins Exclusive Nasdaq Trading
November 27, 2021 | markets.businessinsider.com
Silence Therapeutics : Update on AIM Delisting
November 16, 2021 | proactiveinvestors.com
Silence Therapeutics: Data and clinical progress will be the catalysts, says London broker
November 11, 2021 | finance.yahoo.com
Silence Therapeutics to Present at Jefferies London Healthcare Conference
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SLN Company Calendar

Last Earnings
9/14/2020
Today
3/24/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:SLN
CUSIP
N/A
CIK
N/A
Web
www.silence-therapeutics.com
Phone
+44-20-34576900
Fax
N/A
Employees
74
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.80
Current Ratio
4.52
Quick Ratio
4.36

Sales & Book Value

Annual Sales
£11.35 million
Price / Sales
42.34
Cash Flow
GBX 84.41 per share
Price / Cash Flow
6.34
Book Value
GBX 18.20 per share
Price / Book
29.40

Miscellaneous

Outstanding Shares
89,785,000
Free Float
N/A
Market Cap
£480.35 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Mark Andrew Rothera (Age 58)
    Pres, CEO & Exec. Director
    Comp: $521.23k
  • Dr. Giles V. Campion M.D. (Age 67)
    Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director
    Comp: $436.2k
  • Mr. Craig A. Tooman M.B.A. (Age 55)
    MBA, Chief Financial Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corp. Communications
  • Dr. Barbara A. Ruskin (Age 61)
    Sr. VP, Gen. Counsel & Chief Patent Officer
  • Ms. Linnea Elrington
    VP & Head of HR
  • Dr. John Strafford
    VP & Head of Bus. Devel.
  • Mr. Jørgen Wittendorff
    Sr. VP & Head of Manufacturing
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Sr. VP & Head of Molecular Design

Key Competitors

View All Competitors













SLN Stock - Frequently Asked Questions

How have SLN shares performed in 2023?

Silence Therapeutics' stock was trading at GBX 535 at the beginning of the year. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535.
View the best growth stocks for 2023 here.

How were Silence Therapeutics' earnings last quarter?

Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Monday, September, 14th. The company reported ($13.70) earnings per share for the quarter, topping analysts' consensus estimates of ($21.70) by $8.00.

What other stocks do shareholders of Silence Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA).

What is Silence Therapeutics' stock symbol?

Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN."

How do I buy shares of Silence Therapeutics?

Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Silence Therapeutics' stock price today?

One share of SLN stock can currently be purchased for approximately GBX 535.

How much money does Silence Therapeutics make?

Silence Therapeutics (LON:SLN) has a market capitalization of £480.35 million and generates £11.35 million in revenue each year.

How can I contact Silence Therapeutics?

Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at +44-20-34576900.

This page (LON:SLN) was last updated on 3/24/2023 by MarketBeat.com Staff